BioCentury
ARTICLE | Clinical News

Akcea starts Phase IIb of AKCEA-APOCIII-LRx in hypertriglyceridemia

January 12, 2018 7:24 PM UTC

Akcea Therapeutics Inc. (NASDAQ:AKCA) began a double-blind, placebo-controlled Phase IIb trial to evaluate four doses of AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx) in 100 patients with hypertriglyceridemia and established cardiovascular disease (CVD). AKCEA-APOCIII-LRx is a ligand conjugated antisense version of an oligonucleotide targeting apolipoprotein C-III (APOCIII; APOC3).

The trial's primary endpoints are safety and reduction in serum triglyceride levels from baseline to six months. Secondary endpoints include reduction in serum levels of APOCIII and serum levels of cholesterol parameters. Akcea expects top-line data in 2019...